HOW DO THE JUDGES SELECT THE SCRIP AWARDS WINNERS?
The Scrip Awards prides itself on its independent Judging Panel, comprised of independent, senior industry experts from around the world, each chosen for their knowledge, objectivity and credibility. The judges each separately consider entries from those categories that are relevant to their particular areas of specialist knowledge, expertise and experience (where they have no conflicts of interest), ensuring a considered response to each individual submission. Each category is reviewed by at least three judges.
Brown is an independent pharmaceutical project management, QA and training consultant, and course director for the MSc programme in clinical research at the University of Cardiff’s School of Pharmacy. She has more than 20 years of experience of managing clinical development projects, and training in the pharmaceutical industry. She has worked in project management for several companies including Wellcome, Hoechst Marion Roussel, Good Clinical Research Practices and LB Training and Development. She is also co-author of several books including, Project Management for the Pharmaceutical Industry.
Dix is one of the UK’s leading pharma and biotech entrepreneurs. He has more than 25 years’ experience life sciences, with over 20 years in senior pharmaceutical industry positions, and a degree and PhD in Pharmacology.
Dix is currently CEO of C4X Discovery plc and Chairman of Centauri Therapeutics Ltd and Touchlight Ltd, and is also a non-executive director of the Medicines Discovery Catapult. Dix was formerly co-founder and chief executive of Convergence Pharmaceuticals Ltd., a pain-specialist pharmaceuticals company acquired by Biogen Idec in 2015. Previously he had been a founder and CEO of PowderMed Ltd, and chair of Auralis Ltd. Before that Dix was held R&D roles at PowderJect Pharmaceuticals plc until its acquisition by Chiron Vaccines in 2003, and GlaxoWellcome.
Gillings is recognised as a visionary pioneer in the contract research organisation industry. He is co-founder and former executive chairman of Quintiles Transnational, the world’s largest biopharmaceutical services company. Gillings retired as executive chairman in 2015, although he remains on the board of the Fortune 500 company.
In 2014, Gillings was appointed World Dementia envoy by former UK Prime Minister David Cameron. In this capacity he chaired the World Dementia Council, an organization that seeks to stimulate innovation to treat cognitive decline.
As envoy, he worked with governments to provide a global leadership role in addressing the economic, regulatory and social barriers to innovation in dementia prevention, treatment, and care. Gillings has seen firsthand the devastating effects of dementia and lack of effective treatment, as his mother lived with the condition for 18 years until her death in 2013.
Prior to founding Quintiles, Gillings was a professor of biostatistics at the University of North Carolina at Chapel Hill for more than 15 years. Among the many honours he has received, Gillings was awarded a CBE in 2004 for services to the pharmaceutical industry. In 2012, he received the SCRIP Lifetime Achievement Award in recognition of contributions to pharmaceuticals.
Halloran is the president of Halloran Consulting Group, founded in 1998. With over 30 years in life science management, she has become recognized as an industry expert through her group’s work in bringing world-class expertise to plan and build early-stage life science companies, and to transform and restore large life science companies to nimble and high quality organizations.
In 2017 Halloran was awarded Enterprising Woman of the Year and in 2015, Halloran was honored by the Boston Business Journal as a Woman of Influence. The company has received a ranking in the INC 500 fastest growing companies for the past three years. In 2010, Halloran was selected as one of the 100 Most Inspiring People in Life Science by PharmaVoice and in 2009, she was awarded clinical researcher of the year by ACRP.
Hargreaves is an independent adviser for private equity. His career in healthcare spans academia, pharma, venture capital and private equity.
Following his early career as a lecturer in pharmacy at Manchester University, he had a series of commercial and international marketing roles with Smith Kline and French, Mundipharma, Wellcome, Glaxo Wellcome and with Astra Hässle which included the commercialisation of the blockbuster Nexium. In 1997, he moved to 3i plc in the innovative growth period of biotech venture capital. More recently he originated several significant growth capital deals and buyouts.
Hargreaves currently advises selected private equity firms and spends a proportion of his time in the charity sector.
Jones is chair of Simbec-Orion Group and Director Arix Bioscience plc. He was formerly R&D director of The Wellcome Foundation, a director of Allergan Inc. and director general of the Association of the British Pharmaceutical Industry (ABPI). He is a visiting professor at King’s College, London
Mehta founded and is managing member of Mehta Partners, LLC. His analytical insights on global healthcare have influenced bio-pharmaceutical strategy and investments worldwide. Educated at the University of Southern California and UCLA, he has worked with senior biopharma leaders and investment managers for over 30 years.
Mehta’s career began with Merck & Co. in international strategic planning and competitor analysis. This foundation prompted Wood MacKenzie & Company Inc. to invite him to establish a pharmaceutical research function in New York. This effort was expanded at S.G. Warburg & Company, and led to the formation of the BioPharma investment advisory group Mehta and Isaly, now known as Mehta Partners.
Gather Health is Mehta ‘s new initiative to empower patients while enhancing physician productivity. Gather Health brings together healthcare providers and patients’ social networks, enabling patients to get real-time and active resources and motivation to improve outcomes.
Since 2012, Messom has been chairman of the Institute of Clinical Research; the oldest independent membership-led professional body for global clinical researchers. With a background in molecular genetics, Messom has almost 20 years’ industry experience working both within pharmaceutical companies and clinical research organisations.
Messom has detailed experience of directing global clinical trials and has worked in a wide variety of leadership roles, within pharma companies and CROs not only for project and monitoring teams, but also data management, outsourcing, informatics and translational medicine departments. Most recently she has provided consultancy support to an academic group working on a translational medicine project and operational consultancy to a mid-sized pharma company working in Phase III and IV.
Phacharintanakul is chair of Strategic Business Partners in Bangkok, Thailand. Until the end of 2004 he was chair of the board at Aventis Thailand, where he previously held a range of posts including managing director and marketing manager. Before joining Aventis, he was on the secretariat of the United Nations Economic Commission for Asia and the Pacific. Phacharintanakul also acts as an expert advisor for the Thailand Center of Excellence for Life Sciences.
Pitts is president of the Center for Medicine in the Public Interest. A former member of the United States Senior Executive Service, Pitts was the FDA’s associate commissioner for external relations, serving as senior communications and policy adviser to the commissioner. He supervised the FDA’s Office of Public Affairs, Office of the Ombudsman, Office of Special Health Issues, Office of Executive Secretariat, and Advisory Committee Oversight and Management. He served on the agency’s obesity working group and counterfeit drug taskforce and is a Special Government Employee consultant to the FDA’s Risk Communications Advisory Committee.
His specific areas of global policy expertise include FDA policy and process, healthcare technology assessment and reimbursement issues, biosimilar development, Rx-to-OTC switching, risk management plans, GMP policies, pharmacy education programs, drug safety, DTC/ItP, Critical Path, personalized medicine, clinical trial transparency, IP protection, FDA reform, drug importation, counterfeiting, genetically modified food issues, food safety and security, recalls, and nutritional labeling.
Schinazi is the Frances Winship Walters Professor of Pediatrics and Director of the Laboratory of Biochemical Pharmacology at Emory University and co-Director of the HIV Cure Scientific Working Group for the NIH-sponsored Emory University Center for AIDS Research. Schinazi has authored over 500 peer-reviewed papers and seven books and holds over 100 issued US patents, which have resulted in 15 NDAs.
A world leader in nucleoside chemistry, Schinazi is best known for his pioneering work on HIV, HBV and HCV drugs stavudine, lamivudine, emtricitabine, telbivudine, and most recently sofosbuvir. More than 94% of HIV-infected individuals in the US on combination therapy take at least one of the drugs he invented.
After 35 years of service, Schinazi retired from the Department of Veterans Affairs with his latest position as senior research career scientist. Schinazi was appointed to the Global Virus Network executive committee in 2016.
Smith began his career as a scientist in the research and development division of ICI and then SmithKline Beecham. After completing his PhD in Molecular Biology at the University of Nottingham and with Glaxo, after then an MBA, Smith switched to a commercial role at SB Pharmaceuticals and was appointed global brand manager for Bactroban and new products in the Anti-Infectives Global Marketing Group. In 2000, Smith moved into asset management and venture capital at 3i Group and subsequently held the position of lead fund manager for three life science specific funds – 3i Bioscience Investment Trust PLC, International Biotechnology Trust PLC, and AXA Framlington Biotech Fund. Smith was awarded the Techmark technology fund manager of the year for 2007.
After leaving AXA in 2010, Smith held appointments as director of business development at the Oxfordshire Bioscience Network and head of corporate finance at PharmaVentures. Smith has also taught the life science company valuation, finance and analysis module on the University of Cambridge MPhil program for over ten years. Smith returned to specialist fund management in 2012 to manage the Magna Biopharma Income Fund.
In 2017 Andy moved to the Pricing & Market Access group at ICON in London where he advises big pharma and smaller life science companies on the valuation and commercialisation of their products.
Spiegel is the founder of Spiegel Consulting, an independent advisory firm to pharma and biotechnology companies. He retired in 2009 as chief medical officer at Schering-Plough. With more than 25 years of experience in the pharmaceutical industry he played a significant role in the development of novel biologics and drugs as senior vice-president of Worldwide Clinical Research. Spiegel is a fellow of the American College of Physicians and has received numerous awards and fellowships. He serves as an advisor to Warburg Pincus and the Israeli Biotech Fund and on the boards of numerous biotechnology companies and non-profit organizations. He is an assistant professor Weill Cornell Medical School and associate fellow in the University of Pennsylvania Center for Bioethics.
Tempest has worked in the pharmaceutical industry for the last 46 years and in that time has managed healthcare businesses around the globe. Between 1995 and 2007 he held senior executive positions, including president, CEO and vice-chairman at Ranbaxy Laboratories. Previously, Tempest was Far East regional director for GlaxoSmithKline in the Far East, Middle East and Africa. Today, as Chairman of Hale & Tempest, he advises companies, banks, investment funds, private equity and high net-worth individuals on their strategy in Asia. Tempest is a non-executive director of SRL Diagnostics, Fortis Healthcare, Touch Digital Media, Religare Capital Markets and Glenmark Pharmaceuticals. Currently he is Editor of the Journal of Generic Medicines and a non-executive director of the United Nations Medicines Patent Pool.
Thong consults on business strategy and collaborations in the bioscience sector, and writes a regular blog on these topics, SciTechStrategy. Thong’s full-length book, Biopharma R&D Partnerships: From David & Goliath to Networked R&D, was published in January 2016, derived from the practical experiences of over forty different organisations. He has previously been co-head of the Cap Gemini Life Sciences Group, managing director of Datamonitor’s healthcare division, a non-executive board member of the listed US mid-sized pharmaceutical company Alpharma, and a co-founder of two specialist consultancies focusing respectively on mid-sized biopharma companies and change management for scientific organisations.
Winter is the Master of Trinity College, Cambridge and a Fellow of the Royal Society and until recently a member of the Medical Research Council’s Laboratory of Molecular Biology (LMB) in Cambridge. He is a scientist, inventor and entrepreneur and best known for his research and inventions relating to therapeutic antibodies made at the LMB.
He has founded three biotech companies based on his inventions: Cambridge Antibody Technology in 1989 (bought by AstraZeneca), Domantis in 2000 (bought by GlaxoSmithKline) and Bicycle Therapeutics in 2009.
Scrip Awards is part of the Business Intelligence Division of Informa PLC